Skip to main content

NUWE

Stock
Health Care
Medical Devices

Performance overview

NUWE Price
Price Chart

Forward-looking statistics

Beta
0.76
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Nuwellis Inc is a medical device company. Its solutions includes Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.

Company info

SectorHealth Care
IndustryMedical Devices
Employees54
Market cap$3.8M

Fundamentals

Enterprise value-$1.1M
Revenue$8.8M
Revenue per employee
Profit margin-112.09%
Debt to equity13.73

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$630.42
Dividend per share
Revenue per share$3.70
Avg trading volume (30 day)$106M
Avg trading volume (10 day)$23M
Put-call ratio

Macro factor sensitivity

Growth+2.8
Credit+9.4
Liquidity-1.1
Inflation-1.4
Commodities+6.2
Interest Rates+7.6

Valuation

Dividend yield0.00%
PEG Ratio-0.08
Price to sales0.16
P/E Ratio-0.08
Enterprise Value to Revenue-0.13
Price to book0.24

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

Nuwellis, Inc. (NUWE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $20.98 per share a year ago.

Zacks Investment Research (May 13, 2025)
DaVita, Nuwellis Extend Pilot Collaboration for Aquadex

DaVita DVA recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis NUWE until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years.

Benzinga (June 11, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free